SecBot SecBot
6-K ·Filed Nov 3, 2026

FMS

Fresenius Medical Care AG
BEARISH
Impact 6/10
Horizonmonths Processed13d 18h ago SEC0001104659-26-121730
6-K: Earnings release
Actionable Insight ▼ Bearish

The Q3 results show accelerating margin pressure from inflation, restructuring costs, and declining treatment volumes in the U.S. The new CEO's strategy update and the pace of FME25+ savings realization will be key to watch. The CMS 2027 ESRD PPS final rule (2.7% aggregate increase) provides a modest tailwind, but the negative TDAPA reimbursement impact is expected to increase in Q4.

DirectionBearish
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

Fresenius Medical Care reported Q3 2026 revenue of EUR 4.937B, up 1% as reported (down 1% constant currency) from EUR 4.885B a year ago. Net income attributable to shareholders fell 42% to EUR 160M (EUR 0.61 per share) from EUR 275M (EUR 0.94), driven by higher personnel costs, inflationary pressures, Legacy Portfolio Optimization charges (EUR 98M impact), and lower income from equity method investees. The Care Enablement segment swung to an operating loss of EUR 32M from income of EUR 87M, largely due to the China Strategy Refinement charges.

Key Financial Metrics

EPS
$0.61
est $0.53 · +15.1%
Revenue
$4.9B
est $4.9B · +0.5% · +1.1% YoY
Rating
beat
Free Cash Flow
$1.2B
Gross Margin
25.84%

Key Facts

  • Q3 2026 revenue EUR 4.937B vs EUR 4.885B (+1% reported, -1% constant currency)
  • Operating income EUR 384M vs EUR 477M (-19% reported, -19% constant currency)
  • Net income attributable to shareholders EUR 160M vs EUR 275M (-42%)
  • Basic EPS EUR 0.61 vs EUR 0.94 (-35%)
  • Care Enablement segment operating loss of EUR 32M vs income of EUR 87M
  • Legacy Portfolio Optimization impact on operating income: EUR 98M in Q3 2026 vs EUR 50M in Q3 2025
  • FME25+ Program costs EUR 54M in Q3 2026 vs EUR 41M in Q3 2025
  • Same Market Treatment Growth in U.S. declined 1.1% in Q3 2026
  • Value-Based Care segment revenue fell 7% to EUR 537M from EUR 576M
  • Share buyback: 33.9M shares repurchased for EUR 776M in first nine months of 2026
  • CEO change: Shervin J. Korangy appointed effective October 12, 2026

Financial Impact

Q3 2026 operating income declined EUR 93M year-over-year; net income attributable to shareholders fell EUR 115M. Legacy Portfolio Optimization charges of EUR 98M and FME25+ costs of EUR 54M weighed on results.

revenueoperating incomenet incomeEPSsegment operating income

Segment Breakdown

SegmentRevenueGrowth
Care Delivery$3.5B+2.6%
Value-Based Care$536.6M-6.8%
Care Enablement$1.5B+6.7%

Risk Factors

  • U.S. regulatory headwinds from OBBBA Medicaid cuts and Marietta ruling effects on commercial mix
  • China Strategy Refinement (exiting peritoneal dialysis and 4008A system) creates ongoing restructuring charges
  • Elevated inflation and labor costs continuing to pressure margins
  • Declining U.S. Same Market Treatment Growth (-1.1%) due to organizational redesign disruptions
  • Tavneos Impacts (EUR 71M negative in 9M 2026) from revoked marketing authorization

Market Snapshot

Exchange
OTC
Sector
Services-Misc Health & Allied Services, NEC
Analyst Consensus
21% bullish (29 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 9 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001104659-26-121730
Document: fms-ex31d1.htm0001104659-26-121730
Document: fms-ex31d2.htm0001104659-26-121730
Document: fms-ex32d1.htm0001104659-26-121730
Document: fms-ex32d2.htm0001104659-26-121730
Document: 0001104659-26-121730-index-headers.html0001104659-26-121730
Document: 0001104659-26-121730-index.html0001104659-26-121730
Document: 0001104659-26-121730.txt0001104659-26-121730
Earnings Context (Synthetic; results releases only)0001104659-26-121730

Track record

16 reports on FMS

Performance horizon

2 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +3.43% at T+60 after the Apr 7, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 13, 20263d ago SC 13D/A Bearish 5/10 Entry $22.03 Now $21.86 +0.77% settles Nov 20
  2. Nov 9, 20267d ago 6-K Neutral 2/10 Entry $22.95 to $21.86 Now $21.86 −4.75% ▼ −4.75% −3.06% vs SPY
  3. Nov 3, 202613d ago 6-K Bearish 6/10 Viewing No price data
  4. Nov 3, 202613d ago 6-K Bearish 5/10 Entry $21.73 to $22.74 Now $21.86 −0.60% ▼ −4.65% −5.24% vs SPY
  5. Oct 30, 202618d ago Court Ruling Neutral 4/10 Entry $22.61 to $22.95 Now $21.86 −3.32% ▲ +1.50% +1.43% vs SPY
  6. Oct 7, 20265w ago 6-K Neutral 3/10 Entry $20.69 to $21.54 Now $21.86 +5.65% ▲ +4.11% +5.09% vs SPY
  7. Sep 25, 20267w ago 6-K Bearish 5/10 Entry $22.69 to $22.25 Now $21.86 +3.66% ▲ +1.94% +1.72% vs SPY
  8. Sep 1, 202611w ago Court Ruling Neutral 1/10 Entry $22.65 to $22.23 Now $21.86 −3.49% ▼ −1.85% −0.90% vs SPY
  9. Aug 31, 202611w ago GOVT-CONTRACT Neutral 3/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
  10. Aug 31, 202611w ago Court Ruling Neutral 4/10 Entry $22.74 to $22.33 Now $21.86 −3.87% ▼ −1.80% −1.88% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 5h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026